CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia

Dianne Pulte, Richard R. Furman, M. Johan Broekman, Joan H.F. Drosopoulos, Harold S. Ballard, Kim E. Olson, Jorge Kizer, Aaron J. Marcus

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Introduction: Chronic lymphocytic leukemia (CLL) is a B-cell disorder, but it is also associated with abnormalities in T-lymphocyte function. In this study we examine changes in T-lymphocyte CD39 and CD73 expression in patients with CLL. Methods: Blood samples were drawn from 34 patients with CLL and 31 controls. The cells were stained for CD3, CD4, CD8, CD19, CD39, and CD73 and analyzed by flow cytometry. Results: Overall, patients with CLL had a higher percentage of CD39+ T lymphocytes than did controls. The percentage of cells expressing CD39 was higher in both CD4+ cells and CD8+ cells. Higher CD3/CD39 expression was associated with a later disease stage. No correlations between T-lymphocyte CD39 levels and CD38 or Zap-70 expression were observed. In contrast, the percentage of T lymphocytes and B lymphocytes that expressed CD73 was decreased in patients with CLL. Average B-lymphocyte CD73 expression was decreased in CLL because the majority of CLL clones were CD73. However a minority of CLL clones were CD73+, and patients with CD73+ clones tended to have earlier stage disease. Conclusion: T-lymphocyte CD39 and CD73 expression may be useful prognostic markers in patients with CLL. Expression of CD73 on the malignant cell population in CLL may be a marker of better prognosis.

Original languageEnglish (US)
Pages (from-to)367-372
Number of pages6
JournalClinical Lymphoma, Myeloma and Leukemia
Volume11
Issue number4
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
T-Lymphocytes
B-Lymphocytes
Clone Cells
Flow Cytometry

Keywords

  • CD39
  • Chronic lymphocytic leukemia
  • Prognosis
  • T lymphocyte

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Pulte, D., Furman, R. R., Broekman, M. J., Drosopoulos, J. H. F., Ballard, H. S., Olson, K. E., ... Marcus, A. J. (2011). CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia. Clinical Lymphoma, Myeloma and Leukemia, 11(4), 367-372. https://doi.org/10.1016/j.clml.2011.06.005

CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia. / Pulte, Dianne; Furman, Richard R.; Broekman, M. Johan; Drosopoulos, Joan H.F.; Ballard, Harold S.; Olson, Kim E.; Kizer, Jorge; Marcus, Aaron J.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 11, No. 4, 01.01.2011, p. 367-372.

Research output: Contribution to journalArticle

Pulte, Dianne ; Furman, Richard R. ; Broekman, M. Johan ; Drosopoulos, Joan H.F. ; Ballard, Harold S. ; Olson, Kim E. ; Kizer, Jorge ; Marcus, Aaron J. / CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia. In: Clinical Lymphoma, Myeloma and Leukemia. 2011 ; Vol. 11, No. 4. pp. 367-372.
@article{b5ce53ab715247ae9fe6c34a95e2dabf,
title = "CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia",
abstract = "Introduction: Chronic lymphocytic leukemia (CLL) is a B-cell disorder, but it is also associated with abnormalities in T-lymphocyte function. In this study we examine changes in T-lymphocyte CD39 and CD73 expression in patients with CLL. Methods: Blood samples were drawn from 34 patients with CLL and 31 controls. The cells were stained for CD3, CD4, CD8, CD19, CD39, and CD73 and analyzed by flow cytometry. Results: Overall, patients with CLL had a higher percentage of CD39+ T lymphocytes than did controls. The percentage of cells expressing CD39 was higher in both CD4+ cells and CD8+ cells. Higher CD3/CD39 expression was associated with a later disease stage. No correlations between T-lymphocyte CD39 levels and CD38 or Zap-70 expression were observed. In contrast, the percentage of T lymphocytes and B lymphocytes that expressed CD73 was decreased in patients with CLL. Average B-lymphocyte CD73 expression was decreased in CLL because the majority of CLL clones were CD73. However a minority of CLL clones were CD73+, and patients with CD73+ clones tended to have earlier stage disease. Conclusion: T-lymphocyte CD39 and CD73 expression may be useful prognostic markers in patients with CLL. Expression of CD73 on the malignant cell population in CLL may be a marker of better prognosis.",
keywords = "CD39, Chronic lymphocytic leukemia, Prognosis, T lymphocyte",
author = "Dianne Pulte and Furman, {Richard R.} and Broekman, {M. Johan} and Drosopoulos, {Joan H.F.} and Ballard, {Harold S.} and Olson, {Kim E.} and Jorge Kizer and Marcus, {Aaron J.}",
year = "2011",
month = "1",
day = "1",
doi = "10.1016/j.clml.2011.06.005",
language = "English (US)",
volume = "11",
pages = "367--372",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "4",

}

TY - JOUR

T1 - CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia

AU - Pulte, Dianne

AU - Furman, Richard R.

AU - Broekman, M. Johan

AU - Drosopoulos, Joan H.F.

AU - Ballard, Harold S.

AU - Olson, Kim E.

AU - Kizer, Jorge

AU - Marcus, Aaron J.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Introduction: Chronic lymphocytic leukemia (CLL) is a B-cell disorder, but it is also associated with abnormalities in T-lymphocyte function. In this study we examine changes in T-lymphocyte CD39 and CD73 expression in patients with CLL. Methods: Blood samples were drawn from 34 patients with CLL and 31 controls. The cells were stained for CD3, CD4, CD8, CD19, CD39, and CD73 and analyzed by flow cytometry. Results: Overall, patients with CLL had a higher percentage of CD39+ T lymphocytes than did controls. The percentage of cells expressing CD39 was higher in both CD4+ cells and CD8+ cells. Higher CD3/CD39 expression was associated with a later disease stage. No correlations between T-lymphocyte CD39 levels and CD38 or Zap-70 expression were observed. In contrast, the percentage of T lymphocytes and B lymphocytes that expressed CD73 was decreased in patients with CLL. Average B-lymphocyte CD73 expression was decreased in CLL because the majority of CLL clones were CD73. However a minority of CLL clones were CD73+, and patients with CD73+ clones tended to have earlier stage disease. Conclusion: T-lymphocyte CD39 and CD73 expression may be useful prognostic markers in patients with CLL. Expression of CD73 on the malignant cell population in CLL may be a marker of better prognosis.

AB - Introduction: Chronic lymphocytic leukemia (CLL) is a B-cell disorder, but it is also associated with abnormalities in T-lymphocyte function. In this study we examine changes in T-lymphocyte CD39 and CD73 expression in patients with CLL. Methods: Blood samples were drawn from 34 patients with CLL and 31 controls. The cells were stained for CD3, CD4, CD8, CD19, CD39, and CD73 and analyzed by flow cytometry. Results: Overall, patients with CLL had a higher percentage of CD39+ T lymphocytes than did controls. The percentage of cells expressing CD39 was higher in both CD4+ cells and CD8+ cells. Higher CD3/CD39 expression was associated with a later disease stage. No correlations between T-lymphocyte CD39 levels and CD38 or Zap-70 expression were observed. In contrast, the percentage of T lymphocytes and B lymphocytes that expressed CD73 was decreased in patients with CLL. Average B-lymphocyte CD73 expression was decreased in CLL because the majority of CLL clones were CD73. However a minority of CLL clones were CD73+, and patients with CD73+ clones tended to have earlier stage disease. Conclusion: T-lymphocyte CD39 and CD73 expression may be useful prognostic markers in patients with CLL. Expression of CD73 on the malignant cell population in CLL may be a marker of better prognosis.

KW - CD39

KW - Chronic lymphocytic leukemia

KW - Prognosis

KW - T lymphocyte

UR - http://www.scopus.com/inward/record.url?scp=85047689068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047689068&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2011.06.005

DO - 10.1016/j.clml.2011.06.005

M3 - Article

VL - 11

SP - 367

EP - 372

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 4

ER -